Formation of an asymmetric dimer by the EGFR (epidermal growth factor receptor) kinase domains results in allosteric activation. Since this dimer does not readily form in solution, the EGFR kinase domain phosphorylates most peptide substrates with a relatively low catalytic efficiency. Peptide C is a synthetic peptide substrate of EGFR developed by others that is phosphorylated with a significantly higher catalytic efficiency, and we sought to understand the basis for this. Peptide C was found to increase EGFR kinase activity by promoting formation of the EGFR kinase domain asymmetric dimer. Activation of the kinase domain by Peptide C also enhances phosphorylation of other substrates. Aggregation of the EGFR kinase domain by Peptide C probably underlies activation, and Peptide C precipitates several other proteins. Peptide C was found to form fibrils independent of the presence of EGFR, and these fibrils may facilitate aggregation and activation of the kinase domain. These results establish that a peptide substrate of EGFR may increase catalytic activity by promoting kinase domain dimerization by an aggregationmediated mechanism.
INTRODUCTION
The kinase domain of the EGFR (epidermal growth factor receptor; also known as ErbB1) is activated by an allosteric mechanism upon receptor dimerization. The C-lobe (C-terminal lobe) of one kinase subunit (the activator) interacts with the Nlobe (N-terminal lobe) of a second kinase subunit (the receiver) and results in the allosteric activation of the receiver through the formation of an asymmetric dimer of the kinase domains [1] . The recombinant kinase domain of EGFR is predominantly monomeric in vitro and thus does not readily undergo allosteric activation, resulting in very low catalytic activity. A construct of EGFR that includes the cytoplasmic juxtamembrane segment and the kinase domain forms the asymmetric dimer much more readily, and the catalytic efficiency is at least 70-fold higher than for the isolated kinase domain [2, 3] . The catalytic efficiency of the isolated kinase domain can also be increased by tethering it to small unilamellar vesicles, thereby increasing its effective concentration [1] .
The most important substrates of EGFR are tyrosine residues located in the long C-terminal tail of the receptor. When phosphorylated, these tyrosine residues serve as docking sites for effector proteins that relay the signal onward through the cell [4] . Short peptides containing these tyrosine residues ('tail peptides') are poor substrates for the EGFR kinase domain, presumably because efficient phosphorylation of the tail occurs within an EGFR dimer or higher order oligomer [5] [6] [7] . For example, a 15-residue peptide containing Tyr 1173 from the tail of human EGFR, which we refer to as Tail Peptide A, has an estimated value of 1 mM for the Michaelis constant, K m , when phosphorylated by the EGFR kinase domain. Note that the numbering system we use for EGFR does not include the 24 residues of the N-terminal signal sequence.
Researchers at GlaxoSmithKline screened several peptide libraries for EGFR activity and identified a peptide substrate that is phosphorylated with a much higher efficiency than tail peptides (referred to as Peptide C in their work; we retain this name in the present paper) [8] . The value of the catalytic efficiency, k cat /K m , for this peptide was reported to be ∼ 26-fold higher than that for Tail Peptide A [9] . Additional studies with peptides derived from various proteins that are EGFR substrates or from synthetic peptide libraries have identified other peptide substrates for EGFR. Notably, the primary sequence of Peptide C is more hydrophobic than the other peptide substrates, which are predominantly acidic [10, 11] .
Owing to the increased catalytic efficiency of the EGFR kinase domain when Peptide C is used as a substrate, we sought to use Peptide C to develop robust biochemical assays for EGFR. The reported value of K m of 128 μM for Peptide C permits EGFR activity to be measured at saturating peptide concentrations, which is not feasible using tail peptides for which the values of K m are in the low millimolar range [5, 9] . Several other studies have used Peptide C as an EGFR substrate peptide due to these favourable catalytic parameters [12] [13] [14] .
The present study confirms the remarkable activity of EGFR with Peptide C, but also reveal unexpected properties that are likely to be undesirable in studies of EGFR enzymatic activity. We find that the value of k cat /K m for Peptide C in our assays is over 250-fold increased when directly compared with Tail Peptide A. We confirm that the high activity with Peptide C requires formation of the asymmetric dimer of EGFR kinase domains. Furthermore, the activity of EGFR with Peptide C as a substrate shows a steep dependence on the concentration of Peptide C, with a Hill coefficient of nearly 3. This behaviour suggested to us initially that the peptide could be binding at an allosteric site on EGFR and thereby promoting kinase dimerization and increased
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activity. However, a detailed analysis of Peptide C found that it most likely stimulates EGFR activity by promoting aggregation of the kinase domain. Previous reports have described the ability of other molecules to aggregate and activate EGFR, and Peptide C represents the first peptide substrate of EGFR shown to have this effect [15] [16] [17] .
MATERIALS AND METHODS

Protein expression and purification
The EGFR kinase domain construct (residues 672-998 of the processed human EGFR, UniProt accession number P00533) was expressed and purified as described previously [1] . Mutations were introduced by the QuikChange ® mutagenesis kit (Strategene) and confirmed by sequencing. All constructs assayed included the N-terminal His 6 tags.
Peptide substrates
The peptide substrates were produced by solid-phase synthesis and purified by HPLC to a purity of at least 90 % as analysed by MS. The sequence of Peptide C is RAHEEIYHFFFAKKK [8] .
The sequence of Tail Peptide A is RRKGSTAENAEYLRV and is derived from the Tyr 1173 autophosphorylation site of EGFR [18] . The sequence of Tyrsub is EELEDDYEDDMEE and is derived from the human erythrocyte protein Band 3 [10] .
Enzyme-coupled kinase assays
The enzyme-coupled kinase assay was performed as described previously [19] . EGFR kinase domain concentration was either 2 μM for assays with Peptide C or 8 μM for assays with Tail Peptide A or Tyrsub. In experiments in which pairs of different kinase domain dimerization mutants were assayed, each kinase domain was assayed at 1 μM for a total kinase domain concentration of 2 μM. Peptide concentrations were varied as indicated. The ATP concentration was 500 μM. Buffer conditions were 10 mM MgCl 2 and 20 mM Tris, pH 7.5. Assays were performed at room temperature (22 • C). Values for the kinetic parameters k cat and K m for Tail Peptide A and Tyrsub were derived from fits to the Michaelis-Menten equation using Prism, version 5.0c (GraphPad). Because the data for Peptide C fit better to a sigmoidal curve, the Top and EC 50 values that were derived in the Hill analysis, which is described in the subsequent section, were used as the values for k cat and K m respectively for EGFR catalysis with Peptide C.
Hill analysis
Hill coefficients were derived from fitting data to the Log(Agonist) against Response, Variable Slope equation defined as y = Bottom + (Top − Bottom)/{1 + 10ˆ[(log EC 50 − x)×HillSlope]} using Prism, version 5.0c (GraphPad), in which y is the specific rate of catalysis, Top and Bottom are maximum and minimum specific rates respectively, EC 50 is the concentration of peptide at which half of the maximum specific rate is attained, and x is the base-10 logarithm of the substrate concentration. Because the Tail Peptide A and Tyrsub analysis did not reach saturating concentrations, better fits for the Hill analysis were obtained when the Top (k cat ) values were constrained to those derived from the Michaelis-Menten fits.
Immunoblot analysis
Autophosphorylation reactions were performed with 800 nM EGFR kinase domain, 500 μM ATP, 10 mM MgCl 2 , 20 mM Tris, pH 7.5, 400 μM NaF, 1 mM Na 3 VO 4 and Peptide C at the indicated concentrations in a 30 μl volume at room temperature. Reactions were terminated after 1 min by the addition of 20 mM EDTA. Samples were run on SDS/PAGE gels and subjected to immunoblot analysis. Levels A variant of Peptide C with the sequence RAHEEIAHFFFAKKK was included at the indicated concentrations. Reaction mixtures were terminated by the addition of 60 μl of 0.5% phosphoric acid, and 55 μl of the quenched reaction mixture was spotted on to each of two P81 phosphocellulose filter discs (Whatman). The discs were filtered and washed three times with 0.5 % phosphoric acid using a vacuum manifold (Hoefer Scientific Instruments). UniverSol scintillation cocktail (5 ml; MP Biomedicals) was added to the dried discs in scintillation vials, and the radiation was measured by liquid scintillation counting (Beckman Coulter).
Precipitation analysis
Samples of Peptide C at indicated concentrations and 2 μM wildtype EGFR kinase domain, I682Q EGFR kinase domain or BSA (Sigma-Aldrich) were incubated in 10 mM Tris, pH 7.5, 20 mM NaCl and 0.02 % polysorbate 20 in a total volume of 75 μl for approximately 20 min at room temperature. The samples were centrifuged at 15 800 g for 10 min at 4
• C. Supernatants were removed, and pelleted materials were resuspended and resolved by SDS/PAGE. The bands were quantified by densitometry in ImageJ (NIH) [20] .
DLS (dynamic light scattering) measurements
Samples of 1 mM Peptide C in water, 20 mM NaCl or assay buffer (15 mM Tris, pH 7.5, 0.02 % polysorbate 20 and 20 mM NaCl) were analysed by DLS at 25
• C using a DynaPro Titan (Wyatt). Measurements were made with the 60 mW laser at 15 % power and at an angle of 90
• . Buffer components were filtered prior to measurements. The filter retained Peptide C and as a result the peptide could not be filtered.
TEM (transmission electron microscopy)
Samples of Peptide C at indicated concentrations with and without 2 μM wild-type or I682Q EGFR kinase domain were prepared in 10 mM Tris, pH 7.5, 20 mM NaCl and 0.02 % polysorbate 20 and incubated for approximately 10 min at room temperature. An Table 1 Kinetic parameters for EGFR kinase domain activity with EGFR peptide substrates
The specific rates of EGFR kinase domain catalysis as a function of peptide concentration were fitted to the Michaelis-Menten equation to derive the catalytic rate constant k cat and Michaelis constant K m for Tail Peptide A and Tyrsub. Because the curve generated for specific rate as a function of peptide concentration for Peptide C is sigmoidal, the values of k cat and K m are instead derived from fitting the data to the Hill equation ( Figure 1A ). Specific rates for each of the peptides were measured in at least triplicate using the enzyme-coupled kinase assay with either 2 or 8 μM EGFR kinase domain for Peptide C or Tail Peptide A and Tyrsub respectively. Peptide sequences are: Peptide C, RAHEEIYHFFFAKKK; Tail Peptide A, RRKGSTAENAEYLRV; and Tyrsub, EELEDDYEDDMEE. The values are means + − S.E.M. and generated from data points measured in at least triplicate. aliquot (6 μl) of the samples was adsorbed on Formvar carboncoated 400 mesh copper grids (Electron Microscopy Sciences), and the grids were negatively stained with three applications of 6 μl of 1% (w/v) uranyl acetate. The grids were viewed with a JEOL 1200 EX transmission electron microscope.
RESULTS AND DISCUSSION
Analysis of catalytic parameters and co-operativity for EGFR peptide substrates
We used a spectrophotometric enzyme-coupled kinase assay to characterize the kinetic parameters for Peptide C phosphorylation by EGFR in comparison with two other peptide substrates, Tail Peptide A and Tyrsub, a 13-residue peptide based on a sequence from human erythrocyte protein Band 3 [10, 19] . We were unable to reach saturating levels with Tail Peptide A and Tyrsub, and thus their catalytic parameters are estimates based on fits to the Michaelis-Menten equation (Supplementary Figure S1 at http://www.biochemj.org/bj/453/bj4530337add.htm). Peptide C does indeed stimulate EGFR kinase activity, with a catalytic rate constant, k cat , of 0.160 s − 1 that is approximately 8-fold higher than that for Tail Peptide A (0.021 s − 1 ) and Tyrsub (0.019 s − 1 ) ( Table 1 ). More dramatically, the value of the Michaelis constant, K m , for Peptide C (30 μM) is greatly decreased relative to the low millimolar values obtained for the peptides with natural sequences. Taken together, the catalytic efficiency (k cat /K m ) for Peptide C is approximately 250-and 760-fold higher than those for Tail Peptide A and Tyrsub respectively, confirming that Peptide C is a very efficient substrate for EGFR.
The rate of EGFR-catalysed phosphorylation rises steeply in response to increased Peptide C concentration, and fitting of the data to the Hill equation confirms positive co-operativity with a Hill coefficient of ∼ 2.8 ( Figure 1A ). Conversely, Tail Peptide A and Tyrsub exhibit little or no co-operativity ( Figures 1B and 1C) . The observed co-operativity with Peptide C suggested that the peptide might achieve its high catalytic efficiency by a mechanism not employed by the other peptide substrates.
Peptide C stimulates phosphorylation of other substrates
Although the activation of the EGFR kinase domain relies principally on formation of the asymmetric dimer, phosphorylation of Tyr 845 in the activation loop of the kinase domain is also expected to increase activity [21] . We wondered whether Peptide C could increase the catalytic activity of Hill coefficients for EGFR kinase domain catalysis with EGFR kinase peptide substrates (A) Peptide C, (B) Tail Peptide A and (C) Tyrsub were derived by fitting the specific rates of catalysis at log 10 (peptide concentration) to the Hill equation using Prism software by GraphPad. Because the Tail Peptide A and Tyrsub measurements did not attain saturating concentrations, better fits for the Hill analysis were obtained when the Top (k cat ) values were constrained to those derived from the Michaelis-Menten fits (Table 1 and Supplementary Figure S1 at http://www.biochemj.org/bj/453/bj4530337add.htm). Specific rates for each of the peptides were measured using the enzyme-coupled kinase assay with either 2 or 8 μM EGFR kinase domain for Peptide C or Tail Peptide A and Tyrsub respectively. Data points are the means + − S.E.M. from a minimum of three replicates, and n H (Hill coefficient) values are means + − S.E.M.
EGFR by increasing phosphorylation of Tyr 845 . Immunoblotting with a phospho-Tyr 845 -specific antibody confirmed that Tyr 845 phosphorylation increased in a dose-dependent manner with addition of Peptide C (Figures 2A and 2B) . Surprisingly, the same dose-dependent increase in phosphorylation was observed for the tyrosine residues in the truncated C-terminal tail that is within the kinase domain construct, Tyr 974 and Tyr 992 , indicating that Peptide C generally increases the rate of EGFR kinase domain autophosphorylation (Figures 2A and 2B) . Phosphorylation of EGFR at Tyr 845 only resulted in a slight increase in in vitro catalytic activity, and so autophosphorylation at Tyr 845 does not account for the marked increase in activity observed with Peptide C (Supplementary Figure S2 at http://www.biochemj. org/bj/453/bj4530337add.htm).
The increase in autophosphorylation in the presence of Peptide C suggested that phosphorylation of other peptide substrates may also be promoted. To test this, we measured the phosphorylation of Tail Peptide A in a radiometric assay in the presence of a Peptide C variant in which the tyrosine residue was replaced with an alanine residue. This variant peptide cannot be phosphorylated by EGFR. Phosphorylation of Tail Peptide A by EGFR increased in Autophosphorylation reactions were performed with 800 nM EGFR kinase domain for 1 min and terminated by the addition of EDTA prior to immunoblotting with antibodies specific for EGFR and each phosphotyrosine residue. Band densities were quantified using ImageJ and normalized to EGFR kinase domain levels [20] . Values are relative to the maximum levels of phosphorylation for each phosphotyrosine residue. Data points are the means + − S.E.M from a minimum of three replicates. (C) Phosphorylation of Tail Peptide A [γ -phosphoryl (γ -P) incorporated)] was measured in a radiometric kinase assay in the presence of a Peptide C variant in which the substrate tyrosine residue was replaced by alanine and could not undergo phosphorylation. Reactions were performed for 10 min with 500 nM EGFR kinase domain, 750 μM Tail Peptide A, Peptide C variant at indicated concentrations, and 25 μM ATP labelled with 8.325 μCi/ml [γ -32 P]ATP and terminated by the addition of 0.5 % phosphoric acid. Reactions were spotted on to filters, and the radioactivity was quantified by liquid scintillation counting. Data points are the means + − S.E.M. from four replicate filters.
response to the concentration of the Peptide C variant ( Figure 2C ). Interestingly, the activity profile with the Peptide C variant resembled that of Peptide C itself; the EC 50 is 45 μM and an approximate fit to the Hill equation yields a Hill coefficient of ∼ 2.4 (Supplementary Figure S3 at http://www.biochemj.org/bj/ 453/bj4530337add.htm). Thus the ability of Peptide C to stimulate EGFR activity is apparently independent of its role as a substrate.
Increased EGFR activity with Peptide C requires formation of the asymmetric dimer
We wondered whether Peptide C promotes the formation of the asymmetric dimer as a mechanism to increase the catalytic activity of EGFR. Such a mechanism could also underlie the observed positive co-operativity. To test whether asymmetric dimer formation is required, we utilized EGFR kinase domain constructs (A) The specific rates of catalysis of the EGFR kinase domain dimerization mutants I682Q, which is on the N-lobe, and V924R, which is on the C-lobe, either alone or combined were measured over a titration of Peptide C. (B) The kinase-inactivating mutation D813N was introduced into each of the I682Q and V924R dimerization mutants, and specific rates for each of the kinase domain pairs I682Q/D813N with V924R or I682Q with D813N/V924R over a titration of Peptide C were measured. (C) Hill coefficients for the pairs of I682Q and V924R or I682Q/D813N and V924R were derived by fitting the specific catalytic rates from (A) and (B) at log 10 (peptide concentration) to the Hill equation using Prism software by GraphPad. Specific rates at indicated Peptide C concentrations were measured using the enzyme-coupled kinase assay. All measurements were made using 2 μM total kinase domain, and 1 μM of each of the mutant kinase domains when measured as a pair. Data points are the means + − S.E.M. from a minimum of three replicates, and n H (Hill coefficient) values are means + − S.E.M.
bearing mutations that block formation of the asymmetric dimer. One mutation, I682Q, is located on the N-lobe of the kinase domain and restricts the mutant kinase domain to serve only as an activator. The second mutation, V924R, is on the C-lobe and restricts the mutant kinase domain to being a receiver. When assayed independently, neither of these mutants alone is sufficient to produce high activity. However, combining the two mutants at high effective concentrations permits reconstitution of the asymmetric dimer [1] . The activating properties of Peptide C are entirely abrogated when assayed with either the I682Q or V924R mutants alone. However, when the two mutant EGFR kinase domains are combined, catalysis is regained to approximately 60 % of that of the wild-type kinase domain ( Figure 3A ). Therefore the ability to form the asymmetric dimer is required for activation by Peptide C. In the EGFR asymmetric dimer only the receiver is activated, and this might explain why lower activity is observed with the combination of the V924R and I682Q kinase domains than for the wild-type protein.
The requirements for catalytic activity of the activator and receiver kinase domains were tested by assaying kinase Co-sedimentation of (A) wild-type EGFR kinase domain, (B) I682Q EGFR kinase domain and (C) BSA in the presence of Peptide C is visualized by representative SDS/PAGE gels, and (D) band densities of the precipitated proteins were quantified. Each protein (2 μM) was incubated with 0-175 μM Peptide C for 20 min and centrifuged, and the resuspended pellets were resolved by SDS/PAGE. Band densities were quantified using ImageJ [20] . Data points are the means + − S.E.M. from a minimum of three replicates.
domains in which a catalytic residue, Asp 813 , was mutated to asparagine (D813N), a mutation commonly made to inactivate kinases [22] . The combination of the inactive mutant activator I682Q/D813N and competent receiver V924R exhibited nearly identical activity with Peptide C to the combination of I682Q and V924R ( Figure 3B ). Alternatively, inactive mutant receiver D813N/V924R paired with competent activator I682Q had no catalytic activity, as expected from the asymmetric dimer model. Taken together, these results indicate that the mechanism by which Peptide C stimulates EGFR catalysis is consistent with formation of the asymmetric dimer; both activator and receiver kinase domains are required for activation, but only the receiver undergoes activation [1] .
The dimerization mutants exhibit similar co-operativity with Peptide C to wild-type EGFR
The increases in the specific rate in response to titration of Peptide C for the pairs of EGFR kinase domain dimerization mutants occurs with high co-operativity, similar to what was observed with the wild-type EGFR kinase domain. The Hill coefficients derived from fitting the data to the Hill equation were ∼ 3.0 and ∼ 2.5 for the V924R kinase domain assayed with the I682Q and I682Q/D813N kinase domains respectively, and are similar to the Hill coefficient of ∼ 2.8 for the wild-type kinase domain ( Figure 3C ). This result is unexpected, as we expected that the high co-operativity of the wild-type kinase domain with Peptide C might result from the ability of the kinase domain to oligomerize as a chain through the asymmetric dimer interface as seen in crystal structures [1, 23] . The I682Q and V924R kinase domain mutants should not, however, form chains when combined, and so the high values of the Hill coefficients observed with these combinations could not be rationalized.
Aggregation may also give rise to steep dose-response curves, and in this case high Hill coefficients are often transferable between assays and enzymes [24] . Previous work has shown the abilities of several molecules to aggregate EGFR, and aggregation of EGFR correlates with increased kinase activity [15] [16] [17] . We hypothesized that, likewise, Peptide C could increase catalytic efficiency by functioning as an aggregator of the EGFR kinase domain.
Peptide C precipitates the EGFR kinase domain
To test the capacity of Peptide C to aggregate EGFR, we incubated the kinase domain with Peptide C, pelleted the insoluble materials and resolved the samples by SDS/PAGE. The kinase domain precipitated as a function of Peptide C concentration, and the Peptide C concentration-dependence of precipitation resembled that for kinase activity (Figures 4A and 4D ). The correlation of aggregation and activation of EGFR in the presence of Peptide C suggests two possibilities. Peptide C could promote the active conformation and consequently the aggregation of the kinase domain. EGFR kinase domain constructs that are more catalytically active also have a higher propensity to aggregate [25] . Alternatively, Peptide C may aggregate EGFR, and the asymmetric dimer is stabilized as a by-product of aggregation.
Peptide C precipitates proteins and forms aggregates on its own
To clarify the connection between activity and aggregation, we tested the ability of Peptide C to precipitate additional proteins. Peptide C precipitated the I682Q dimerization mutant EGFR kinase domain similarly to the wild-type kinase domain ( Figures 4B and 4D ). This suggests that kinase activity is not required for precipitation and rather that activation occurs as result of aggregation. Furthermore, Peptide C appears to precipitate other proteins. BSA precipitated in the presence of Peptide C over the same concentration range of the peptide, although with a higher apparent EC 50 ( Figures 4C and 4D ). These data suggest that Peptide C precipitates proteins over a narrow concentration range and that this precipitation appears to be linked to the dimerizationmediated activation of the EGFR kinase domain.
We monitored the aggregation of Peptide C by itself in solution using DLS and found that the peptide alone is sufficient to form aggregates. A 1 mM solution of the peptide in water exhibited limited aggregation, and the hydrodynamic radius of the sample was almost entirely described by a polydisperse distribution of 1-10 nm. Preparation of 1 mM Peptide C in an assay buffer (15 mM Tris, pH 7.5, 0.02 % polysorbate 20 and 20 mM NaCl) resulted in a highly aggregated sample with very low mobility, which was indicated by a spike in laser intensity and minimal decay within the intensity autocorrelation decay function (Supplementary Figure S4 at http://www.biochemj.org/ There appears to be lower levels of EGFR in solution at high Peptide C concentrations, and the fibril edges are less defined. Samples were incubated for approximately 10 min prior to being deposited on Formvar carbon grids. The grids were negatively stained with 1 % uranyl acetate and viewed using a JEOL 1200 EX transmission electron microscope. Scale bars, 100 nm. bj/453/bj4530337add.htm). A 1 mM Peptide C sample in 20 mM NaCl showed aggregation to an intermediate degree between the aqueous solution and the buffered samples. Thus Peptide C has a propensity to form large aggregates in solution, and aggregation of Peptide C appears to be increased by the addition of other solutes.
Electron microscopy shows that Peptide C forms fibrils
We examined samples of Peptide C in the absence and presence of EGFR kinase domain by TEM to gain an insight into the structures formed during aggregation. Samples of Peptide C at concentrations of 20, 40 and 80 μM all deposit as clumps of flexible fibrils that are several hundreds of nanometers in length (Figures 5A-5C ). The overall morphology of the fibrils appeared to be independent of Peptide C concentration. Globular aggregates closely associated with the fibrils were also observed ( Figures 5A-5C, arrows) . The TEM images show that Peptide C formed fibrils at concentrations relevant to the activation of EGFR. Additionally, the globular aggregates formed by Peptide C and any monomeric, well-behaved Peptide C, which cannot be visualized by TEM, may also be important for activation of EGFR with Peptide C. The predominance and homogeneity of the fibrils suggests that if Peptide C is present in a monomeric form, the transition of Peptide C to the fibrillar state is co-operative.
We also examined samples of Peptide C in the presence of the EGFR kinase domain to try to establish a link between Peptide C and EGFR kinase domain aggregation and activation. Fibrils similar to those formed by Peptide C alone as well as globular aggregates localized near the fibrils were observed in all samples containing Peptide C (Figures 5E and 5F ). The addition of the EGFR kinase domain caused the edges of the fibrils to appear less crisp, suggesting that EGFR might associate with the surface of the fibrils. EGFR in samples without Peptide C formed numerous small aggregates on the grid, and these were also observed in the sample with 20 μM Peptide C (Figures 5D and 5E ). These small dispersed aggregates were not observed in samples of EGFR kinase domain with 80 μM Peptide C, which suggests that free EGFR becomes depleted from solution in the presence of increasing amounts of Peptide C ( Figure 5F ). This observation is consistent with our studies of EGFR precipitation as a function of Peptide C concentration.
Additionally, we examined samples of the I682Q EGFR kinase domain with different concentrations of Peptide C, and the samples appeared indistinguishable from wild-type (Supplementary Figure S5 at http://www.biochemj.org/bj/453/bj4530337add. htm). This indicates that the ability of EGFR to dimerize and activate does not grossly affect its interactions with Peptide C. The nature of the interaction between the EGFR kinase domain and Peptide C that underlies activation of the kinase domain remains unknown.
Conclusions
In the present study we have shown that Peptide C, a peptide selected for enhanced phosphorylation by EGFR, serves as a highly efficient substrate by aggregating EGFR. Aggregation appears to occur non-specifically, but, because the activity of EGFR depends on the local concentration of the kinase domain, aggregation of EGFR by Peptide C results in formation of the asymmetric dimer and EGFR kinase domain activation. It has been shown previously that poly-lysine, poly-arginine, sphingosine and protamine can aggregate and activate EGFR in an apparently co-operative manner, although it is not known whether these molecules form macromolecular assemblies such as those formed by Peptide C [16, 17] . Peptide C appears to be the first such molecule, though, that serves as an EGFR substrate in addition to increasing kinase activity by an aggregation-mediated mechanism. All of these previously studied aggregators of EGFR are positively charged, and Peptide C contains an N-terminal arginine residue and three C-terminal lysine residues, suggesting that a positive charge within the aggregating molecule may be required to aggregate EGFR.
The fibrils formed by Peptide C might provide a surface on which the EGFR can dimerize and activate. A similar mechanism has been observed for the allosteric activation of procaspase-3 upon binding to the surface of fibrils formed by a small molecule [26] . Our TEM data show that the edges of the fibrils are less clearly defined when the EGFR kinase domain is present, suggesting that the kinase domain may be associated with the surface of the fibrils.
Peptide C activates EGFR via formation of the asymmetric dimer. In one possible scenario, the fibrils formed by Peptide C might serve as a surface on which the EGFR kinase domain may bind to undergo aggregation and activation. This strategy resembles activation at the cell membrane, in which ligand binding to the full-length receptor causes dimerization and activation [4] . The present paper studying Peptide C joins the growing body of evidence that recognizes the importance of EGFR asymmetric dimer formation in a concentration-dependent manner as the mechanism underlying kinase activation [1, 27, 28] .
The phosphorylation of Peptide C by EGFR occurs with a desirable catalytic efficiency, and as a result other studies have utilized Peptide C as a substrate for EGFR [12] [13] [14] . Despite the apparent excellent catalytic parameters of the peptide, Peptide C must be employed as a substrate with caution to avoid misinterpreting data as reflecting EGFR mechanism instead of the unusual properties of Peptide C.
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